team
Receptos is a small molecule drug discovery and development company that leverages proprietary GPCR cell- and protein-based screening with receptor structure determination to enable rational drug development for high-value GPCR targets. Located in San Diego, California, Receptos is privately held with a proven track record of Founder and Management success. MORE »
news
April 22, 2012
Team Receptos raised over $14,000 in donations at the 2012 Walk MS event held at Legoland on Sunday April 22, 2012.
… MORE »
February 16, 2012
Receptos Scientists Publish Determination of a High Resolution
Sphingosine 1-Phosphate Receptor 1 Structure in Science… MORE »
pipeline
RPC1063 has entered a single-ascending and multiple-ascending dose design Phase 1 clinical safety study under a US Investigational New Drug (IND) application. The study will generate data to confirm that the characteristics of RPC1063 meet pre-specified pharmacokinetic, pharmacodynamic, and safety criteria. The Phase 1 study is anticipated to conclude in early 2012, paving the way for a Phase 2 proof-of-concept study in patients with relapsing-remitting MS. MORE »